Show simple item record

dc.contributor.authorGarcía-Silva J
dc.contributor.authorUlloa-Gutierrez R
dc.contributor.authorIvankovich-Escoto G
dc.contributor.authorYamazaki-Nakashimada M.A
dc.contributor.authorFaugier-Fuentes E
dc.contributor.authordel Águila O
dc.contributor.authorCamacho-Moreno G
dc.contributor.authorEstripeaut D
dc.contributor.authorGutiérrez I.F
dc.contributor.authorCastillo-Bustamante D
dc.contributor.authorLuciani K
dc.contributor.authorFabi M
dc.contributor.authorEspada G
dc.contributor.authorÁlvarez-Olmos M.I
dc.contributor.authorSilfa C
dc.contributor.authorPérez-Camacho P
dc.contributor.authorDuarte-Passos S
dc.contributor.authorCervi M.C
dc.contributor.authorMartínez-Ramírez R.O
dc.contributor.authorCantillano E.M
dc.contributor.authorLlamas-Guillén B.A
dc.contributor.authorVelásquez-Méndez M
dc.contributor.authorSaltigeral-Simental P
dc.contributor.authorCriales J
dc.contributor.authorFernández-Sarmiento J
dc.contributor.authorChacon-Cruz E
dc.contributor.authorGarcía-Domínguez M
dc.contributor.authorAguilar K.L.B
dc.contributor.authorVillarreal-Treviño A.V
dc.contributor.authorTremoulet A.H.
dc.date.accessioned2024-10-07T21:39:21Z
dc.date.available2024-10-07T21:39:21Z
dc.date.issued2024
dc.identifier.issn27727076
dc.identifier.otherhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85203086490&doi=10.1016%2fj.ijregi.2024.100419&partnerID=40&md5=1017f58d7287f64d24e25c1eb95caf67
dc.identifier.urihttp://hdl.handle.net/10818/61895
dc.description.abstractObjectives: Our aim was to describe the epidemiology and outcomes of multisystem inflammatory syndrome in children (MIS-C) in Latin America. Methods: We conducted an observational, retrospective, and prospective multicenter study that gathered information from 84 participating centers across 16 Latin American countries between August 1, 2020 and June 30, 2022. Results: Of the 1239 reported children with MIS-C, 84.18% were previously healthy. The most frequent clinical manifestation in our studied population was abdominal pain (N = 804, 64.9%), followed by conjunctival injection (N = 784, 63.3%). The median duration of fever at the time of hospital admission was 5 days and a significant number of subjects required admission to an intensive care unit (N = 589, 47.5%). Most of the subjects (N = 1096, 88.7%) were treated with intravenous immunoglobulin, whereas 76.7% (N = 947) were treated with steroids, of whom 10.6% (N = 100) did not receive intravenous immunoglobulin. The death rate attributed to MIS-C was 4.88%, with a rate of 3.39% for those initially diagnosed with MIS-C and 8.85% for those whose admission diagnosis was not MIS-C (P <0.001, odds ratio 2.76, 95% confidence interval 1.6-4.6). Conclusions: One of the most significant findings from our study was the death rate, especially in those not initially diagnosed with MIS-C, in whom the rate was higher. This highlights the importance of increasing awareness and making an earlier diagnosis of MIS-C in Latin America. © 2024 The Author(s)en
dc.formatapplication/pdfes_CO
dc.language.isoenges_CO
dc.publisherIJID Regionses_CO
dc.relation.ispartofseriesIJID Regions Vol. 12 N° art. 100419
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabanaes_CO
dc.sourceIntellectum Repositorio Universidad de La Sabanaes_CO
dc.subject.otherLatin Americaen
dc.subject.otherMultisystem Inflammatory Syndrome in Children (MIS-C)en
dc.titleMultisystem inflammatory syndrome in children across 16 Latin American countries: A multicenter study from the REKAMLATINA Networken
dc.typejournal articlees_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO
dc.identifier.doi10.1016/j.ijregi.2024.100419


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcept where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International